All Stories

  1. Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment

    Article • Blood and Lymphatic Cancer Targets and Therapy, July 2015, Dove Medical Press

    Dr Joëlle Wiels